11th Circ. Won't Rehear FTC Androgel Pay-For-Delay Case

Law360, New York (July 18, 2012, 7:37 PM EDT) -- The Eleventh Circuit refused Wednesday to reconsider its decision nixing the Federal Trade Commission's antitrust challenge to patent settlements Solvay Pharmaceuticals Inc. inked with several generics makers to protect its blockbuster drug Androgel, despite the watchdog's claims that the ruling let weak patents limit competition.

The decision — a per curiam order from the panel that handed down a strongly-worded opinion tossing the FTC's challenge in April — comes as little surprise from a circuit that has repeatedly rejected antitrust suits over so-called pay-for-delay deals in...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.